Progress Report 2019-20 Executive Officers of the University of Michigan Health System:Marschall S
Total Page:16
File Type:pdf, Size:1020Kb
Progress Report 2019-20 Executive Officers of the University of Michigan Health System:Marschall S. Runge, MD, PhD, Executive Vice President for Medical Affairs and Dean, U-M Medical School; David C. Miller, MD, Executive Vice Dean for Clinical Affairs; Steven L. Kunkel, PhD, Executive Vice Dean for Research. The Regents of the University of Michigan: Jordan B. Acker; Michael J. Behm; Mark J. Bernstein; Paul W. Brown; Sarah Hubbard; Denise Ilitch; Ron Weiser; Katherine E. White; Mark S. Schlissel, (ex officio). Nondiscrimination Policy: The University of Michigan, as an equal opportunity/affirmative actionemployer, complies with all applicable federal and state laws regarding nondiscrimination and affirmative action. The University of Michigan is committed to a policy of equal opportunity for all persons and does not discriminate on the basis of race, color, national origin, age, marital status, sex, sexual orientation, gender identity, gender expression, disability, religion, height, weight, or veteran status in employment, educational programs and activities, and admissions. Inquiries or complaints may be addressed to the Senior Director for Institutional Equity, and Title IX/Section 504/ADA Coordinator, Office for Institutional Equity, 2072 Administrative Services Building, Ann Arbor, Michigan 48109-1432, (734) 763-0235, TTY (734) 647-1388, institutional. [email protected]. For other U-M information call (734) 764-1817. © 2021, The Regents of the University of Michigan. 北京大学医学部 - 密西根大学医学院 Table of Contents Attendees browse the poster Letter from the co-Directors 2 session of the 2019 Joint Institute Symposium in Beijing. Leadership 3 About the JI 4 Vital Statistics 5 New Projects for 2019 6-9 Publications 10-13 Global Executive Education 14-15 2019 JI Symposium 16 LDC Members Provide Insight, Stability 17 Exploring ENT Collaborations with PKU First Hospital 17 2019 Symposium Scrapbook 18-19 COVID-19 Response 20-21 COVID-19 JI Project Highlight 22-23 Celebrating 10 Years of the JI 24-25 Project Updates 26 MD-PhD Program Update 27 Project Highlight 28 Other JI News 29 www.puuma.org | Page 1 Michigan Medicine - PKUHSC Letter from the Co-Directors Colleagues, We are pleased to present the latest progress update for the Joint Institute. This report comes at a most unusual time – not just in our partnership, but more broadly global health – as the world continues to struggle with COVID-19. The timeframe covered in this document has been extended from one to two years so as to include the JI response to the pandemic. Prior to the onset of COVID-19, our collaboration was thriving. We were coming off from yet another successful symposium at the Peking University Health Science Center campus in Beijing. An impressive crop of new projects marked the growth of our collaboration into new areas, including precision medicine and cancer research, as we prepared to mark the 10-year anniversary of our partnership. In short, we were flourishing when a never-before-seen respiratory illness changed everything. At each of our institutions, the pandemic demanded an all-hands-on-deck approach to save lives, protect our healthcare workers, and accelerate discovery as we struggled to learn all we could about the virus that would soon be known as SARS-CoV-2. Still, even amidst the initial response, our two institutions remained in contact. We exchanged critical clinical best practices and insights in the pandemic’s early stages, followed by research ideas across different disciplines impacted by the illness. One COVID-19 JI project is already underway with others anticipated in the near future. In Mandarin, the word crisis is represented by two distinct characters: 危机. The first, unsurprisingly, meansdanger . But the second is the character for opportunity. In the context of a pandemic that (as of this writing) has killed nearly two million and sickened tens of millions around the world, we believe it is important to keep these words in mind. The danger is profound, yet so is the opportunity for this and other international partnerships to address this challenge. Thanks to our long-standing collaboration, the friendships we’ve forged, and the trust we’ve developed, our JI is well positioned to do just that. In the process, we look forward to continuing to demonstrate not just the viability of our partnership, but more importantly, its value to medical discovery for the world. Xièxiè. 谢谢. Joseph C. Kolars, MD, MACP Qimin Zhan, MD Co-Director, Joint Institute Co-Director, Joint Institute Senior Associate Dean for President, Peking University Health Education and Global Initiatives Science Center Josiah Macy, Jr., Professor of Health Executive Vice President, Peking University Professions Education University of Michigan Medical School Page 2 北京大学医学部 - 密西根大学医学院 Leadership Marschall S. Runge, MD, PhD Qimin Zhan, MD Executive Vice President for President, Peking University Health Medical Affairs Science Center Dean, University of Michigan Executive Vice President, Peking Medical School University CEO, Michigan Medicine Director, State Key Laboratory of Molecular Oncology John M. Carethers, MD Ning Zhang, PhD John G. Searle Professor and Vice President, Peking University Chair, Department of Internal Health Science Center Medicine University of Michigan Medical School Rebecca Cunningham, MD Weimin Wang, MD Vice President for Research Vice President, Peking University University of Michigan Health Science Center Professor of Emergency Professor of Surgery Medicine Director, Injury Prevention Center Steven L. Kunkel, PhD Yangfeng Wu, MD, PhD Executive Vice Dean for Executive Associate Director, Research, Chief Scientific Officer Peking University Clinical Peter A. Ward Distinguished Research Institute University Professor Professor, School of Public Endowed Professor of Pathology Health, PKUHSC Research University of Michigan Medical School Joseph C. Kolars, MD, MACP Liping Duan, MD, PhD Senior Associate Dean Vice President, Peking University for Education and Global Health Science Center Initiatives Professor of Internal Medicine Josiah Macy, Jr., Professor of Health Professions Education University of Michigan Medical School www.puuma.org | Page 3 Michigan Medicine - PKUHSC About the JI History In 2010, Michigan Medicine, the academic medical center of the University of Michigan, and Peking University Health Science Center (PKUHSC) established the Joint Institute for Translational & Clinical Research, commonly known at both institutions as the JI. Michigan Medicine and PKUHSC each contributed an initial $7 million and both renewed their financial commitment with repeat $7 million investments in 2015. The JI was established to benefit both partner institutions by: • enhancing translational research capacity; • bolstering a qualified workforce in both basic science and clinical research; • promoting student and faculty exchange; and • helping faculty succesfully compete for extramural PKU Third Hospital faculty and administrators on a UM campus tour as part of their funding. Global Executive Education Program experience. The JI allows faculty at both institutions to partner on research that neither side could conduct alone, advancing health for populations across both the US and China, and beyond. Programs & Cores Much of the research focuses on four key Program areas of interest to both institutions: cardio- vascular, liver, pulmonary, and renal diseases. At the same time, Infrastructure Cores – Biorepository and Biomedical Informatics; IRB and Human Protection; Collaboration – help the partners overcome specific challenges or concerns associated with global collaboration. In 2017, leaders designated two new areas for future project investment and focus: cancer research and preci- sion health. The JI’s collaborative model of mutually agreed-upon organ-based programs supported by administrative cores makes the JI a unique partnership platform between the two institutions. Page 4 北京大学医学部 - 密西根大学医学院 Vital Statistics Vital Statistics To Date 59 86 29 13 9 K $27M JI Awards Completed Projects Patients Enrolled in Studies Publications Extramural Funding Research Areas Awards by Program Area (2011-2019) The JI fosters scientific research across many disciplines. At the Other: 17 outset, cardiovascular, renal, Renal: 10 pulmonary, and gastrointestinal/ Cancer: 3 liver medicine were prioritized. Over the years, other disciplines Pulmonary: 7 Cardiovascular: 14 have been added. Most recently, JI leaders decided to prioritize GI/Liver: 9 research in the areas of cancer treatment and precision health. To date, 59 projects have received funding from nearly 200 submitted proposals. JI Publications (2011-2020) Publications 18 *2020 figure reflects only part JI research has produced 86 16 of the academic year publications to date, 60 of 14 which are co-authored by the 12 respective PIs from each institution. 10 JI research has appeared in 8 leading academic medical 6 journals including Science, 4 Academic Medicine, PLoS ONE, 2 Gastroenterology, and others. 0 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16 ‘17 ‘18 ‘19 ‘20* Funding Institutional investments made through the JI are intended to seed Institutional & Extramural Funding (2011-2020) pilot projects that can ultimately $14M garner extramural funding. To date, JI teams have received more than $12M Extramural Awards $28 million in extramural funding $10M for research as a result of their $8M Institutional JI Funding collaborations. Cardiovascular medicine research alone has $6M resulted in $14 million in extramural $4M funding. Teams